Dual function of nitric oxide in carcinogenesis, reappraisal

Current Drug Metabolism

Volumn 12, Issue 9, 2011, Pages 891-899

  Engin, Ayse Basak ^a  

^a GAZI UNIVERSITY   (Turkey)

Author keywords

3 dioxygenase; Carcinogenesis; Cyclooxygenase; DNA repair; Indolamine 2; Inducible nitric oxide synthase; Lipooxygenase; Nitric oxide; P53; Tetrahydrobiopterin

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE; LIPOXYGENASE; NITRIC OXIDE; PROSTAGLANDIN SYNTHASE; PROTEIN P53; REACTIVE NITROGEN SPECIES; TETRAHYDROBIOPTERIN;

ANTINEOPLASTIC ACTIVITY; CARCINOGENESIS; CHRONIC INFLAMMATION; DNA REPAIR; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; HUMAN; NONHUMAN; REVIEW;

EID: 80053520912     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920011797470092     Document Type: Review

References (114)

1. Lala, P.K.; Chakraborty C. Role of nitric oxide in carcinogenesisand tumour progression. Lancet Oncol., 2001, 2(3), 149-156. (Pubitemid 33585926)
2. Wink, D.A.; Feelisch, M.; Fukuto, J.; Chistodoulou, D.;Jourd'heuil, D.; Grisham, M.B.; Vodovotz, Y., Cook, J.A.; Krishna,M.; DeGraff, W.G.; Kim, S.; Gamson, J.; Mitchell, J.B. Thecytotoxicity of nitroxyl, possible implications for thepathophysiological role of NO. Arch. Biochem. Biophys., 1998;351(1), 66-74. (Pubitemid 28373052)
3. Alderton, W.K.; Cooper, C.E.; Knowles, R.G. Nitric oxidesynthases, Structure, function and inhibition. Biochem. J., 2001,357(Pt3), 593-615. (Pubitemid 32735142)
4. Griffith, O.W.; Stuehr, D.J. Nitric oxide synthases, Properties andcatalytic mechanism. Annu Re Physiol., 1995, 57, 707-736.
5. Hattori, R.; Sase, K.; Eizawa, H.; Kosuga, K.; Aoyama, T.; Inoue.R.; Sasayama, S.; Kawai, C.; Yui, Y.; Miyahara, K.; et al. Structureand function of nitric oxide synthases. Int. J. Cardiol., 1994, 47(1Suppl), S71-S75. (Pubitemid 124013276)
6. Miclescu, A.; Gordh, T. Nitric oxide and pain, something old,something new. Acta Anaesthesiol. Scand., 2009, 53(9), 1107-1120.
7. Rao, C.V. Nitric oxide signaling in colon cancer chemoprevention.Mutat. Res., 2004, 555(1-2), 107-119. (Pubitemid 39345400)
8. Lancaster, J.R.; Jr, Xie, K. Tumors face NO problems? CancerRes., 2006, 66(13), 6459-6462.
9. Becker, Y. Success and failure of dendritic cell (DC) anticanceractivity may be modulated by nitric oxide synthetase (NOS) geneexpression, a hypothesis. In Vivo, 1993, 7(3), 285-288. (Pubitemid 23205708)
10. Jenkins, D.C.; Charles, I.G.; Thomsen, L.L.; Moss, D.W.; Holmes,L.S.; Baylis, S.A.; Rhodes, P., Westmore, K.; Emson, P.C.;Moncada, S. Roles of nitric oxide in tumor growth. Proc. Natl.Acad. Sci. USA, 1995, 92(10), 4392-4396.
11. Thomas, D.D.; Espey, M.G.; Ridnour, L.A.; Hofseth, L.J.;Mancardi, D.; Harris, C.C.; Wink, D.A. Hypoxic inducible factor1alpha, extracellular signal-regulated kinase, and p53 are regulatedby distinct threshold concentrations of nitric oxide. Proc. Natl.Acad. Sci. USA, 2004, 10(24), 8894-8899. (Pubitemid 38781582)
12. Ridnour, L.A.; Thomas, D.D.; Donzelli, S.; Espey, M.G.; Roberts,D.D.; Wink, D.A.; Isenberg, J.S. The biphasic nature of nitric oxideresponses in tumor biology. Antioxid. Redox Signal, 2006, 8(7-8),1329-1337. (Pubitemid 44182431)
13. Ames, B.N.; Gold, L.S.; Willett, W.C. The causes and preventionof cancer. Proc. Natl. Acad. Sci., 1995, 9(12), 5258-5265.
14. Federico, A.; Morgillo, F.; Tuccillo, C.; Ciardiello, F.; Loguercio,C. Chronic inflammation and oxidative stress in humancarcinogenesis. Int. J. Cancer, 2007, 121(11), 2381-2386. (Pubitemid 350022406)
15. Lin, C.W.; Shen, S.C.; Ko, C.H.; Lin, H.Y.; Chen, Y.C. Reciprocalactivation of macrophages and breast carcinoma cells by nitricoxide and colony-stimulating factor-1. Carcinogenesis, 2010,31(12), 2039-2048.
16. Schetter, A.J.; Heegaard, N.H.; Haris, C.C. Inflammation andcancer, interweaving microRNA, free radical, cytokine and p53pathways. Carcinogenesis, 2010, 31(1), 37-49.
17. Kroncke, K.D. Nitrosative stress and transcription. Biol. Chem.,2003, 384(10-11), 1365-1377.
18. Wink, D.A.; Mitchell, J.B. Chemical biology of nitric oxide,insights into regulatory, cytotoxic, and cytoprotective mechanismof nitric oxide. Free Radic. Biol. Med., 1998, 25(4-5), 434-456. (Pubitemid 28390299)
19. Beckman, J.S.; Ischiropoulos, H.; Zhu, L.; van der Woerd, M.;Smith, C.; Chen, J.; Harrison, J.; Martin, J.C.; Tsai, M. Kinetics of superoxide dismutase and iron-catalyzed nitration of phenolics byperoxynitrite. Arch. Biochem. Biophys., 1992, 298(2), 438-445.
20. Ischiropoulos, H.; Zhu, L.; Chen, J.; Tsai, M.; Martin, J.C.; Smith,C.D.; Beckman, J.S. Peroxynitrite-mediated tyrosine nitrationcatalyzed by superoxide dismutase. Arch. Biochem. Biophys., 1992,298(2), 431-437.
21. Ischiropoulos, H. Biological tyrosine nitration, apathophysiological function of nitric oxide and reactive oxygenspecies, Arch. Biochem. Biophys., 1998, 356(1), 1-11. (Pubitemid 28364347)
22. Greenacre, S.A.; Ischiropoulos, H. Tyrosine nitration, localization,quantification, consequences for protein function and signaltransduction. Free Radic. Res., 2001, 34(6), 541-581. (Pubitemid 32694646)
23. Knowles, M.E.; McWeeny, D.J.; Couchman, L.; Thorogood, M.Interaction of nitrite with proteins at gastric pH. Nature, 1974,247(439), 288-289.
24. Radi, R. Nitric oxide, oxidants, and protein tyrosine nitration. Proc.Natl. Acad. Sci. USA, 2004, 101(12), 4003-4008. (Pubitemid 38405874)
25. Oldreive, C.; Zhao, K.; Paganga, G.; Halliwell, B.; Rice-Evans, C.Inhibition of nitrous acid-dependent tyrosine nitration and DNAbase deamination by flavonoids and other phenolic compounds.Chem. Res. Toxicol., 1998, 11(12), 1574-1579. (Pubitemid 29013634)
26. Pannala, A.S.; Mani, A.R.; Spencer, J.P.; Skinner, V.; Bruckdorfer,K.R.; Moore, K.P.; Rice-Evans, C.A. The effect of dietary nitrate on salivary, plasma, and urinary nitrate metabolism in human. FreeRadic. Biol. Med., 2003, 34(5), 576-584. (Pubitemid 36254831)
27. Mujoo, K.; Sharin, V.G.; Martin, E.; Choi, B.K.; Sloan, C.;Nikonoff, L.E.; Kots, A.Y.; Murad, F. Role of soluble guanylylcyclase-cyclic GMP signaling in tumor cell proliferation. NitricOxide, 2010, 22(1), 43-50.
28. Ambs, S.; Merriam, W.G.; Ogunfusika, M.O.; Bennett, W.P.;Ishibe, N.; Hussain, S.P.; Tzeng, E.E.; Geller, D.A.; Billiar, T.R.;Haris, C.C. p53 and vascular endothelial growth factor regulatetumor growth of NOS2-expressing human carcinoma cells. Nat.Med., 1998, 4(12), 1371-1376. (Pubitemid 28553458)
29. Guo, S.; Colbert, L.S.; Fuller, M.; Zhang, Y.; Gonzalez-Perez, R.R.Vascular endothelial growth factor receptor-2 in breast cancer.Biochim. Biophys. Acta, 2010, 1806(1), 108-121.
30. Moochhala, S.; Rajnakova, A. Role of nitric oxide in cancerbiology. Free Radic Res, 1999, 31(6), 671-679.
31. Xu, W.; Liu, L.Z.; Loizidou, M.; Ahmed, M.; Charles, I.G. Therole of nitric oxide in cancer. Cell Res., 2002, 12(5-6), 311-320.
32. Juang, S.H.; Xie, K.; Xu, L.; Shi, Q.; Wang, Y.; Yoneda, J.; Fidler,I.J. Suppression of tumorigenicity and metastasis of human renalcarcinoma cells by infection with retroviral vectors harboring themurine inducible nitric oxide synthase gene. Hum. Gene. Ther.,1998, 9(6), 845-854. (Pubitemid 28197371)
33. Hofseth, L.J.; Hussain, S.P.; Wogan, G.N.; Haris, C.C. Nitric oxidein cancer and chemoprevention. Free Radic. Biol. Med., 2003,34(8), 955-968.
34. Crowell, J.A.; Steele, V.E.; Sigman, C.C.; Fay, J.R. Is induciblenitric oxide synthase a target for chemoprevention? Mol. CancerTher., 2003, 2(8), 815-823.
35. Rao, C.V.; Indranie, C.; Simi, B.; Manning, P.T.; Connor, J.R.;Reddy, B.S. Chemopreventive properties of a selective induciblenitric oxide synthase inhibitor in colon carcinogenesis,administered alone or in combination with celecoxib, a selectivecyclooxygenase-2 inhibitor. Cancer Res., 2002, 62(1), 165-170. (Pubitemid 34074001)
36. Yasui, Y.; Kim, M.; Oyama, T.; Tanaka, T. Colorectal carcinogenesis and suppression of tumor development by inhibitionof enzymes and molecular targets. Curr. Enzyme Inhib., 2009, 5, 1-26.
37. Qu, W.; Liu, J.; Dill, A.L.; Saavedra, J.E.; Keefer, L.K.; Waalkes,M.P. V-PROLI/NO, a nitric oxide donor prodrug, protects livercells from arsenic-induced toxicity. Cancer Sci., 2009, 100(3), 382-388.
38. Nguyen, T.; Brunson, D.; Crespi, C.L.; Penman, B.W.; Wishnok,J.S.; Tannenbaum, S.R. DNA damage and mutation in human cellsexposed to nitric oxide in vitro. Proc. Natl. Acad. Sci. USA, 1992,89(7), 3030-3034.
39. Valko, M.; Rhodes, C.J.; Moncol, J.; Izakovic, M.; Mazur, M. Freeradicals, metals and antioxidants in oxidative stress-induced cancer.Chem. Biol. Interact., 2006, 160(1),1-40. (Pubitemid 43227479)
40. Inoue S, Kawanishi S. Oxidative DNA damage induced bysimultaneous generation of nitric oxide and superoxide. FEBS Lett.,1995, 37(1), 86-88.
41. Valko, M.; Leibfritz, D.; Moncol, J.; Cronin, M.T.; Mazur, M.;Telser, J. Free radicals and antioxidants in normal physiologicalfunctions and human disease. Int. J. Biochem. Cell Biol., 2007,39(1), 44-84. (Pubitemid 44566469)
42. ) Jaiswal, M.; LaRusso, N.F.; Nishioka, N.; Nakabeppu, Y.; Gores,G.J. Human Ogg1, a protein involved in the repair of 8-oxoguanine, is inhibited by nitric oxide. Cancer Res., 2001, 61(17),6388-6393. (Pubitemid 32783243)
43. Appella E, Anderson CW. Signaling to p53, breaking theposttranslational modification code. Pathol. Biol. (Paris), 2000,48(3), 227-245. (Pubitemid 30318124)
44. Hofseth, L.J.; Saito, S.; Hussain, S.P.; Espey, M.G.; Miranda,K.M.; Araki, Y.; Jhappan, C.; Higashimoto, Y.; He, P.; Linke, S.P.;Quezado, M.M.; Zurer, I.; Rotter, V.; Wink, D.A.; Appella, E.;Hariss, C.C. Nitric oxide-induced cellular stress and p53activationin chronic inflammation. Proc. Natl. Acad. Sci. USA,2003, 100(1), 143-148. (Pubitemid 36078042)
45. Forrester, K.; Ambs, S.; Lupold, S.E.; Kapust, R.B.; Spillare, E.A.;Weinberg, W.C.; Felley-Bosco, E.; Wang, X.W.; Geller, D.A.;Tzeng, E.; Billiar, T.R.; Hariss, C.C. Nitric oxide-induced p53accumulation and regulation of inducible nitric oxide synthaseexpression by wild-type p53. Proc. Natl. Acad. Sci. USA, 1996,93(6), 2442-2447. (Pubitemid 26104369)
46. Hussain, S.P.; Amstad, P.; Raja, K.; Ambs, S.; Nagashima, M.;Bennett, W.P.; Shields, P.G.; Ham, A.J.; Swenberg, J.A.; Marrogi,A.J.; Haris, C.C. Increased p53 mutation load in noncancerouscolon tissue from ulcerative colitis, a cancer-prone chronicinflammatory disease. Cancer Res., 2000, 60(13), 3333-3337. (Pubitemid 30482141)
47. Stepnik, M. Roles of nitric oxide in carcinogenesis. Protumorigeniceffects. Int. J. Occup. Med. Environ. Health, 2002, 15(3), 219-227.
48. Thomsen, L.L.; Miles, D.W. Role of nitric oxide in tumourprogression, lessons from human tumours. Cancer Metastasis Rev.,1998, 17(1),107-118. (Pubitemid 28194649)
49. Rajnakova, A.; Goh, P.M.; Chan, S.T.; Ngoi, S.S.; Alponat, A.;Moochhala, S. Expression of differantial nitric oxide synthaseisoforms in human normal gastric mucosa and gastric cancer tissue.Carcinogenesis, 1997, 18(9), 1841-1845. (Pubitemid 28134694)
50. Rajnakova, A.; Moochhala, S.; Goh, P.M.; Ngoi, S. Expression ofnitric oxide synthase, syslooxygenase, and p53 in different stagesof human gastric cancer. Cancer Lett., 2001, 172(2), 177-185. (Pubitemid 32889714)
51. Engin, A.B.; Karahalil, B.; Engin, A.; Karakaya, A.E. DNA repairenzyme polymorphisms and oxidative stress in a Turkishpopulation with gastric carcinoma. Mol. Biol. Rep., 2011 Mar 9. [Epub ahead of print][52]
52. Engin, A.B.; Karahalil, B.; Engin, A.; Karakaya, A.E. Oxidative stress, Helicobacter pylori, and OGG1 Ser326Cys, XPC Lys939Gln, and XPD Lys751Gln polymorphisms in a Turkish population with colorectal carcinoma. Genet. Test Mol. Biomarkers, 2010, 14(4), 559-564.
53. Ambs, S.; Bennett, W.P.; Merriam, W.G.; Ogunfusika, M.O.; Oser,S.M.; Harrington, A.M.; Shields, P.G.; Felley-Bosco, E.; Hussain,S.P.; Hariss, C.C. Relationship between p53 mutations andinducible nitric oxide synthase expression in human colorectalcancer. J. Natl. Cancer Inst., 1991, 91(1), 86-88.
54. Lee, S.H.; Kim, C.H. DNA-dependent Protein Kinase Complex, aMultifunctional Protein in DNA Repair and Damage Checkpoint.Mol. Cells, 2002, 13(2), 159-166.
55. Xu, W.; Liu, L.; Smith, G.C.; Charles, G. Nitric oxide upregulatesexpression of DNA-PKcs to protect cells from DNA-damaginganti-tumour agents. Nat. Cell Biol., 2000, 2(6), 339-345.
56. Frit, P.; Canitrot, Y.; Muller, C.; Foray, N.; Calsou, P.; MarangoniE, Bourhis J, Salles B. Cross-resistance to ionizing radiation in amurine leukemic cell line resistan to cis-dichlorodiammineplatinum (II), role of Ku autoantigen. Mol.Pharmacol., 1999, 56(1),141-146. (Pubitemid 29309822)
57. Engin, A.B.; Ergun, M.A.; Yurtcu, E.; Kan, D.; Sahin, G. Effect ofionizing radiation on the pteridine metabolic pathway andevaluation of its cytotoxicity in exposed hospital staff. Mutat. Res.,2005, 585(1-2), 184-192. (Pubitemid 40980432)
58. Mellor, A.L.; Munn, D.H. Tryptophan catabolism and T-celltolerance, immunosuppression by starvation? Immunol. Today,1999, 20(10), 469-473. (Pubitemid 29476077)
59. Hayaishi, O.; Hirata, F.; Ohnishi, T.; Henry, J.P.; Rosenthal, I.;Katoh, A. Indoleamine 2,3-dioxygenase, Incorporation of 18 O2and 18 O2 into the reaction products. J. Biol. Chem., 1997,252(10), 3548-3550.
60. Frumento, G.; Rotondo, R.; Tonetti, M.; Damonte, G.; Benatti, U.;Ferrara, G.B. Tryptophan-derived catabolites are responsible forinhibition of T and natural killer cell proliferation induced byindoleamine 2,3-dioxygenase. J. Exp. Med., 2002, 196(4), 459-468.
61. Moffett, J.R.; Namboodiri, M.A. Tryptophan and the immuneresponse. Immunol. Cell Biol., 2003, 81(4), 247-265.
62. Takikawa, O.; Kuroiwa, T.; Yamazaki, F.; Kido, R. Mechanism ofinterferon-gamma action. Characterization of indoleamine 2,3-dioxygenase in cultured human cells induced by interferon-gammaand evaluation of the enzyme-mediated tryptophan degradation inits anticellular activity. J. Biol. Chem., 1998, 263(4), 2041-2048.
63. Uyttenhove, C.; Pilotte, L.; Théate, I.; Stroobant, V.; Colau, D.;Parmentier, N.; Boon, T.; Van den Eynde, B.J. Evidence for atumoral immune resistance mechanism based on tryptophandegradation by indoleamine 2,3-dioxygenase. Nat. Med., 2003,9(10), 1269-1274. (Pubitemid 37279849)
64. Hassanain, H.; Chon, S.; Gupta, S. Differential regulation of humanindoleamine 2,3-dioxygenase gene expression by interferonsgammaand -alfa . Analysis of the regulatory region of the geneand identification of an interferon-gamma-inducible DNA-bindingfactor. J. Biol. Chem., 1993, 268(7), 5077-5084. (Pubitemid 23081633)
65. Brown, R.R.; Ozaki, Y.; Data, S.P.; Borden, E.C.; Sondel, P.M.;Malone, D.G. Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS. Adv. Exp.Med. Biol., 1991, 294, 425-435.
66. Fallarino, F.; Grohmann, U.; Vacca, C.; Orabona, C.; Spreca, A.;Fioretti, M.C.; Puccetti, P. T cell apoptosis by tryptophancatabolism. Cell Death Differ., 2002, 9, 1069-1077.
67. Stone, T.W.; Darlington, L.G. Endogenous kynurenines as targetsfor drug discovery and development. Nat. Rev. Drug Discov., 2002,1(8), 609-620. (Pubitemid 37361524)
68. Thomas, S.; Mohr, D.; Stocker, R. Nitric oxide inhibitsindoleamine 2,3-dioxygenase activity in interferon-gamma primedmononuclear phagocytes. J. Biol. Chem., 1994, 269(20), 14457-14464.
69. Hibbs, J.B. Jr.; Taintor, R.R.; Vavrin, Z.; Rachlin, E.M. Nitricoxide, a cytotoxic activated macrophage effector molecule.Biochem. Biophys. Res. Commun., 1988, 157(1), 87-94. (Pubitemid 19004828)
70. Aitken, J.B.; Thomas, S.E.; Stocker, R.; Thomas, S.R.; Takikawa,O.; Armstrong, R.S.; Lay, P.A. Determination of the nature of theheme environment in nitrosyl indoleamine 2,3-dioxygenase usingmultiple-scattering analyses of X-ray absorption fine structure.Biochemistry, 2004, 43(17), 4892-4898. (Pubitemid 38552374)
71. Hucke, C.; MacKenzie, C.R.; Adjogble, K.D.; Takikawa, O.;Däubener, W. Nitric oxide-mediated regulation of gammainterferon-induced bacteriostasis, inhibition and degradation ofhuman indoleamine 2,3-dioxygenase. Infect. Immun., 2004, 72(5),2723-2730. (Pubitemid 38542399)
72. Fujigaki, H.; Saito, K.; Lin, F.; Fujigaki, S.; Takahashi, K.; Martin,B.M.; Chen, C.Y.; Masuda, J.; Kowalak, J.; Takikawa, O.;Seishima, M.; Markey, S.P. Nitration and inactivation of IDO byperoxynitrite. J. Immunol., 2006, 176(1), 372-379.
73. Padmaja, S.; Ramazenian, M.S.; Bounds, P.L.; Koppenol, W.H.Reaction of peroxynitrite with L-tryptophan. Redox Rep., 1996, 2,173-177. (Pubitemid 126684617)
74. Yamakura, F.; Ikeda, K. Modification of tryptophan and tryptophanresidues in proteins by reactive nitrogen species. Nitric Oxide,2006, 14(2), 152-161. (Pubitemid 43165881)
75. Al-Hijji, J.; Andolf, E.; Laurini, R.; Batra, S. Nitric oxide synthaseactivity in human trophoblast, term placenta and pregnantmyometrium. Reprod. Biol. Endocrinol., 2003, 51, 2-7.
76. López, A.S.; Alegre, E.; Díaz, A.; Mugueta, C.; González, A.Bimodal effect of nitric oxide in the enzymatic activity ofindoleamine 2,3-dioxygenase in human monocytic cells. Immunol.Lett., 2006, 106(2), 163-171. (Pubitemid 44223745)
77. Weber, W.P.; Feder-Mengus, C.; Chiarugi, A.; Rosenthal, R.;Reschner, A.; Schumacher, R.; Zajac, P.; Mitseli, H.; Frey, D.M.;Oertli, D.; Heberer, M.; Spagnoli, G.C. Differential effects of thetryptophan metabolite 3-hydroxyanthranilic acid on theproliferation of human CD8+ T cells induced by TCR triggering orhomeostatic cytokines. Eur.J. Immunol., 2006, 36(2), 296-304. (Pubitemid 43257452)
78. Samelson-Jones, B.J.; Yeh, S.R. Interactions between nitric oxideand indoleamine 2,3-dioxygenase. Biochemistry, 2006, 45(28),8527-8538. (Pubitemid 44078872)
79. Munn, D.H.; Shafizadeh, E.; Attwood, J.T.; Bondarev, I.; Pashine,A.; Mellor, A.L. Inhibition of T cell proliferation by macrophagetryptophan catabolism. J. Exp. Med., 1999, 189(9), 1363-1372. (Pubitemid 29227522)
80. Muller, A.J.; DuHadaway, J.B.; Donover, P.S.; Sutanto-Ward, E.;Prendergast, G.C. Inhibition of indoleamine 2,3-dioxygenase, animmunoregulatory target of the cancer suppression gene Bin1,potentiates cancer chemotherapy. Nat. Med., 2005, 11(3), 312-319. (Pubitemid 40460560)
81. Simon, S.M.; Schindler, M. Cell biological mechanisms ofmultidrug resistance in tumors. Proc. Natl. Acad. Sci. USA, 1994,91(9), 3497-3504. (Pubitemid 24139457)
82. Shrode, L.D.; Tapper, H.; Grinstein, S. Role of intracellular pH inproliferation, transformation, and apoptosis. J. Bioenerg.Biomembr., 1997, 29(4), 393-399. (Pubitemid 27498419)
83. Thomas, S.R.; Stocker. R. Redox reactions related to indoleamine2,3- dioxygenase and tryptophan metabolism along the kynureninepathway. Redox Rep., 1999, 4(5), 199-220. (Pubitemid 30088218)
84. Brandacher, G.; Winkler, C.; Schroecksnadel, K.; Margreiter, R.;Fuchs, D. Antitumoral activity of interferon-gamma involved inimpaired immune function in cancer patients. Curr. Drug Metab.,2006, 7(6), 599-612. (Pubitemid 44226588)
85. Feder-Mengus, C.; Wyler, S.; Hudolin, T.; Ruszat, R.; Bubendorf,L.; Chiarugi, A.; Pittelli, M.; Weber, W.P.; Bachmann, A.; Gasser,T.C.; Sulser, T.; Heberer, M.; Spagnoli, G.C.; Provenzano, M. Highexpression of indoleamine 2,3-dioxygenase gene in prostate cancer.Eur. J. Cancer, 2008, 44(15), 2266-2275.
86. Engin, A.B.; Engin, A.; Gonul, I.I.; Karamercan, A.; Sepici-Dincel,A.; Dursun, A. Tumor invasion pattern and related serum trytophanand neopterin concentrations in colorectal carcinomas. Pteridines,2010, 21(2), 35.
87. Engin, A.B.; Ozkan, Y.; Fuchs, D.; Yardim-Akaydin, S. Increasedtryptophan degradation in patients with bronchus carcinoma. Eur.J. Cancer Care (Engl), 2010, 19(6), 803-808.
88. Engin AB, Karahalil B, Karakaya AE, Engin A. Exposure toHelicobacter pylori and serum kynurenine-tryptophan ratio inpatients with gastric cancer. Pteridines 2010
89. Peskar, B.M. Role of cyclooxygenase isoforms in gastric mucosaldefence. J. Physiol., 2001, 95(1-6), 3-9. (Pubitemid 33020212)
90. Lin, D.T.; Subbaramaiah, K.; Shah, J.P.; Dannenberg, A.J.; Boyle,J.O. Cyclo-oxygenase-2, a novel molecular target for theprevention and treatment of head and neck cancer. Head Neck,2002, 24(8), 792-799. (Pubitemid 34857307)
91. Gupta, R.A.; DuBois, R.N. Colorectal cancer prevention andtreatment by inhibition of cyclooxygenase-2. Nat. Rev. Cancer,2001, 1(1), 11-21. (Pubitemid 33741877)
92. Brown, J.R.; DuBois, R.N. COX-2, a molecular target forcolorectal cancer prevention. J. Clin. Oncol., 2005, 23(12), 2840-2855. (Pubitemid 46179475)
93. Perez-Sala, D.; Lamas, S. Regulation of cyclooxygenase-2expression by nitric oxide in cells. Antioxid. Redox Signal, 2001,3(2), 231-248. (Pubitemid 32473339)
94. Weinberg, J.B. Nitric oxide synthase 2 and cyclooxygenase-2interactions in inflammation. Immunol. Res., 2000, 22(2-3), 319-341. (Pubitemid 32382243)
95. Liu, Q.; Chan, S.T.F.; Mahendran, R. Nitric oxide inducescyclooxygenase expression and inhibits cell growth in colon cancercell lines. Carcinogenesis, 2003, 24(4), 637-642. (Pubitemid 36592397)
96. Ghosh, N.; Chaki, R.; Mandal, V.; Mandal, S.C. COX-2 as a targetfor cancer chemotherapy. Pharmacol. Rep., 2010, 62(2), 233-244.
97. Uefuji, K.; Ichikura, T.; Mochizuki, H. Cyclooxygenase-2expression is related to prostaglandin biosynthesis andangiogenesis in human gastric cancer. Clin. Cancer Res., 2000,6(1), 135-138. (Pubitemid 30064985)
98. Salvemini, D.; Setle, S.L.; Masferrer, J.L.; Seibert, K.; Currie,M.G.; Needleman, P. Regulation of prostaglandin production bynitric oxide; an in vivo analysis. Br. J. Pharmacol., 1995, 114(6),1171-1178.
99. Blair, I.A. Lipid hydroperoxide-mediated DNA damage. Exp.Gerontol., 2001, 36(9), 1473-1481. (Pubitemid 32768725)
100. Kuhn, H.; Borchert, A. Regulation of enzymatic lipid peroxidation,the interplay of peroxidizing and peroxide reducing enzymes. FreeRadic. Biol. Med., 2002, 33(2), 154-172. (Pubitemid 34775188)
101. Park, S.W.; Lee, S.G.; Song, S.H.; Heo, D.S.; Park, B.J.; Lee,D.W.; Kim, K.H.; Sung, M.W. The effect of nitric oxide oncyclooxygenase-2 (COX-2) overexpression in head and neckcancer cell lines. Int. J. Cancer, 2003, 107(5), 729-738.
102. Chun, K.S.; Cha, H.H.; Shin, J.W.; Na, H.K.; Park, K.K.; Chung,W.Y.; Surh, Y.J. Nitric oxide induces expression ofcyclooxygenase-2 in mouse skin through activation of NF-kappaB.Carcinogenesis, 2004, 25(3), 445-454.
103. Nichol, C.A.; Smith, G.K.; Duch, D.S. Biosynthesis andmetabolism of tetrahydrobiopterin and molybdopterin. Annu. Rev.Biochem., 1985, 54, 729-64.
104. Huang, L.; Abu-Soud, H.M.; Hille, R.; Stuehr, D.J. Nitric oxidegeneratedP420 nitric oxide synthase, Characterization and roles fortetrahydrobiopterin and substrate in protecting against or reversingthe P420 conversion. Biochemistry, 1999, 38(6), 1912-1920.
105. Griscavage, J.M.; Fukuto, J.M.; Komori, Y.; Ignarro, L.J. Nitricoxide inhibits neuronal nitric oxide synthase by interacting with theheme prosthetic group. Role of tetrahydrobiopterin in modulatingthe inhibitory action of nitric oxide. J. Biol. Chem., 1994, 269(34),21644-21649.
106. Kotsonis, P.; Fröhlich, L.G.; Shutenko, Z.V.; Horejsi, R.;Pfleiderer, W.; Schmidt, H.H. Allosteric regulation of neuronalnitric oxide synthase by tetrahydrobiopterin and suppression ofauto-damaging superoxide. Biochem. J., 2000, 346(Pt 3), 767-776. (Pubitemid 30171039)
107. Werner-Felmayer, G.; Werner, E.R.; Fuchs, D.; Hausen, A.;Reibnegger, G.; Schmidt, K.; Weiss, G.; Wachter, H. Pteridinebiosynthesis in human endothelial cells. Impact on nitric oxidemediatedformation of cyclic GMP. J. Biol. Chem., 1993, 268(3),1842-1846. (Pubitemid 23033583)
108. Alp, N.J.; Channon, K.M. Regulation of nitric oxide synthase bytetrahydrobiopterin in vascular disease. Arterioscler. Thromb. Vasc.Biol., 2004, 24(3), 413-420. (Pubitemid 38326132)
109. Milstien, S.; Katusic, Z. Oxidation of tetrahydrobiopterin byperoxynitrite, Implications for vascular endothelium function.Biochem. Biophys. Res. Commun., 1999, 263(3), 681-684. (Pubitemid 29490686)
110. Vásquez-Vivar, J.; Duquaine, D.; Whitsett, J.; Kalyanaraman, B.;Rajagopalan, S. Altered tetrahydrobiopterin metabolism inatherosclerosis implications for use of oxidized tetrahydrobiopterinanalogues and thiol antioxidants. Arterioscler. Thromb. Vasc. Biol.,2002, 22(10), 1655-1661.
111. Kotamraju, S.; Williams, C.L.; Kalyanaraman, B. Statin-inducedbreast cancer cell death, role of inducible nitric oxide and arginasedependentpathways. Cancer Res., 2007, 67(15), 7386-7394. (Pubitemid 47206569)
112. Chen, L.; Zeng, X.; Wang, J.; Briggs, S.S.; O'Neill, E.; Li, J.; Leek,R.; Kerr, D.J.; Harris, A.L.; Cai, S. Roles of tetrahydrobiopterin inpromoting tumor angiogenesis. Am. J. Pathol., 2010, 177(5), 2671-2680.
113. Lu, J.; Wei, Q.; Bondy, M.L.; Yu, T.K.; Li, D.; Brewster, A.;Shete, S.; Sahin, A.; Meric-Bernstam, F.; Wang, L.E. Promoterpolymorphism (-786t>C) in the endothelial nitric oxide synthasegene is associated with risk of sporadic breast cancer in non-Hispanic white women age younger than 55 years. Cancer, 2006,107(9), 2245-2253. (Pubitemid 44665660)
114. Gratton, J.P.; Lin, M.I.; Yu, J.; Weiss, E.D.; Jiang, Z.L.; Fairchild,T.A.; Iwakiri, Y.; Groszmann, R.; Claffey, K.P.; Cheng, Y.C.;Sessa, W.C. Selective inhibition of tumor microvascularpermeability by cavtratin blocks tumor progression in mice. CancerCell, 2003, 4(1), 31-9. (Pubitemid 36904159)